{"filing":{"accession_number":"0001104659-26-089293","cik":"0001072379","ticker":"NWBO","company_name":"NORTHWEST BIOTHERAPEUTICS INC","form":"8-K","filing_date":"2026-07-31","report_date":"2026-07-29","primary_document":"tm2620800d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1072379/000110465926089293/tm2620800d1_8k.htm"},"events":[{"id":22492,"run_id":20348,"accession_number":"0001104659-26-089293","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"Northwest Biotherapeutics entered into a $4.9 million convertible promissory note with Yorkville Advisors convertible at a discount to market price, plus a standby equity subscription agreement for up to $50 million of common shares and a warrant for $2 million of shares. These dilutive financing instruments materially affect shareholder ownership.","company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","filing_date":"2026-07-31","form":"8-K","submitted_at":null,"items":[{"id":22448,"accession_number":"0001104659-26-089293","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Northwest Biotherapeutics entered into a $4.9 million convertible promissory note with Yorkville Advisors that is convertible at the holder's option at a discount to market price, plus a standby equity subscription agreement for up to $50 million of common shares and a warrant for $2 million of shares. These are classic dilutive financing instruments typical of small-cap biotechnology companies raising capital through convertible securities and equity warrants, which materially affect shareholder ownership and are disclosed under Item 1.01 as a material definitive agreement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:29:50.964323+00:00","company_name":"","ticker":null,"filing_date":""},{"id":22449,"accession_number":"0001104659-26-089293","item_number":"2.03","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.65,"reasoning":"Item 2.03 is filed and incorporates Item 1.01 by reference, indicating a material acquisition, disposition, merger, or change of control that creates a direct financial obligation. Without access to Item 1.01 details, the most likely scenario is a debt issuance or acquisition-related financing. The incorporation of Item 1.01 suggests an M\u0026A transaction with financing components, but Item 2.03's specific focus on direct financial obligations points toward debt creation as the primary disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:29:50.964323+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22448,"accession_number":"0001104659-26-089293","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Northwest Biotherapeutics entered into a $4.9 million convertible promissory note with Yorkville Advisors that is convertible at the holder's option at a discount to market price, plus a standby equity subscription agreement for up to $50 million of common shares and a warrant for $2 million of shares. These are classic dilutive financing instruments typical of small-cap biotechnology companies raising capital through convertible securities and equity warrants, which materially affect shareholder ownership and are disclosed under Item 1.01 as a material definitive agreement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:29:50.964323+00:00","company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","filing_date":"2026-07-31"},{"id":22449,"accession_number":"0001104659-26-089293","item_number":"2.03","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.65,"reasoning":"Item 2.03 is filed and incorporates Item 1.01 by reference, indicating a material acquisition, disposition, merger, or change of control that creates a direct financial obligation. Without access to Item 1.01 details, the most likely scenario is a debt issuance or acquisition-related financing. The incorporation of Item 1.01 suggests an M\u0026A transaction with financing components, but Item 2.03's specific focus on direct financial obligations points toward debt creation as the primary disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:29:50.964323+00:00","company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","filing_date":"2026-07-31"}]}